A detailed history of Black Rock Inc. transactions in Cytosorbents Corp stock. As of the latest transaction made, Black Rock Inc. holds 655,805 shares of CTSO stock, worth $636,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares
655,805
Previous 722,435 9.22%
Holding current value
$636,130
Previous $686,000 33.09%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.7 - $1.01 $46,641 - $67,296
-66,630 Reduced 9.22%
655,805 $459,000
Q1 2024

May 10, 2024

SELL
$0.86 - $1.07 $3,341 - $4,156
-3,885 Reduced 0.53%
722,435 $686,000
Q4 2023

Feb 13, 2024

SELL
$1.08 - $1.94 $479 - $861
-444 Reduced 0.06%
726,320 $806,000
Q3 2023

Nov 13, 2023

SELL
$1.86 - $4.03 $61,839 - $133,985
-33,247 Reduced 4.37%
726,764 $1.37 Million
Q2 2023

Aug 11, 2023

BUY
$2.37 - $3.65 $35,803 - $55,140
15,107 Added 2.03%
760,011 $2.73 Million
Q1 2023

May 12, 2023

BUY
$1.79 - $4.17 $5,096 - $11,871
2,847 Added 0.38%
744,904 $2.51 Million
Q4 2022

Feb 13, 2023

BUY
$1.03 - $2.03 $706 - $1,392
686 Added 0.09%
742,057 $1.15 Million
Q3 2022

Nov 14, 2022

SELL
$1.2 - $2.46 $4,304 - $8,824
-3,587 Reduced 0.48%
741,371 $1.01 Million
Q2 2022

Aug 12, 2022

SELL
$1.76 - $3.22 $3.27 Million - $5.97 Million
-1,855,479 Reduced 71.35%
744,958 $1.63 Million
Q1 2022

May 12, 2022

SELL
$2.88 - $4.23 $88,626 - $130,169
-30,773 Reduced 1.17%
2,600,437 $8.3 Million
Q4 2021

Feb 10, 2022

BUY
$4.05 - $8.11 $293,292 - $587,309
72,418 Added 2.83%
2,631,210 $11 Million
Q3 2021

Nov 09, 2021

SELL
$7.0 - $9.71 $576,618 - $799,851
-82,374 Reduced 3.12%
2,558,792 $20.8 Million
Q2 2021

Aug 11, 2021

BUY
$7.55 - $9.42 $19.9 Million - $24.9 Million
2,641,166 New
2,641,166 $19.9 Million

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $42.3M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.